|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Shimada H, Nabeya Y, Okazumi S, et al:
Prediction of survival with squamous cell carcinoma antigen in
patients with resectable esophageal squamous cell carcinoma.
Surgery. 133:486–494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berwick M and Schantz S: Chemoprevention
of aerodigestive cancer. Cancer Metastasis Rev. 16:329–347. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kikuchi T, Daigo Y, Katagiri T, et al:
Expression profiles of non-small cell lung cancers on cDNA
microarrays: identification of genes for prediction of lymph-node
metastasis and sensitivity to anti-cancer drugs. Oncogene.
22:2192–205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kakiuchi S, Daigo Y, Tsunoda T, Yano S,
Sone S and Nakamura Y: Genome-wide analysis of organ-preferential
metastasis of human small cell lung cancer in mice. Mol Cancer Res.
1:485–499. 2003.PubMed/NCBI
|
|
7
|
Kakiuchi S, Daigo Y, Ishikawa N, et al:
Prediction of sensitivity of advanced non-small cell lung cancers
to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–43. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kikuchi T, Daigo Y, Ishikawa N, et al:
Expression profiles of metastatic brain tumor from lung
adenocarcinomas on cDNA microarray. Int J Oncol. 28:799–805.
2006.PubMed/NCBI
|
|
9
|
Taniwaki M, Daigo Y, Ishikawa N, et al:
Gene expression profiles of small-cell lung cancers: molecular
signatures of lung cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
10
|
Yamabuki T, Daigo Y, Kato T, et al:
Genome-wide gene expression profile analysis of esophageal squamous
cell carcinomas. Int J Oncol. 28:1375–1384. 2006.PubMed/NCBI
|
|
11
|
Suzuki C, Daigo Y, Kikuchi T, Katagiri T
and Nakamura Y: Identification of COX17 as a therapeutic target for
non-small cell lung cancer. Cancer Res. 63:7038–7041.
2003.PubMed/NCBI
|
|
12
|
Kato T, Daigo Y, Hayama S, et al: A novel
human tRNA-dihydrouridine synthase involved in pulmonary
carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Furukawa C, Daigo Y, Ishikawa N, et al:
Plakophilin 3 oncogene as prognostic marker and therapeutic target
for lung cancer. Cancer Res. 65:7102–7110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki C, Daigo Y, Ishikawa N, et al: ANLN
plays a critical role in human lung carcinogenesis through the
activation of RHOA and by involvement in the phosphoinositide
3-kinase/AKT pathway. Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishikawa N, Daigo Y, Takano A, et al:
Characterization of SEZ6L2 cell-surface protein as a novel
prognostic marker for lung cancer. Cancer Sci. 97:737–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takahashi K, Furukawa C, Takano A, et al:
The neuromedin u-growth hormone secretagogue receptor
1b/neurotensin receptor 1 oncogenic signaling pathway as a
therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hayama S, Daigo Y, Kato T, et al:
Activation of CDCA1-KNTC2, members of centromere protein complex,
involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kato T, Hayama S, Yamabuki T, et al:
Increased expression of IGF-II mRNA-binding protein 1 is associated
with the tumor progression in patients with lung cancer. Clin
Cancer Res. 13:434–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suzuki C, Takahashi K, Hayama S, et al:
Identification of Myc-associated protein with JmjC domain as a
novel therapeutic target oncogene for lung cancer. Mol Cancer Ther.
6:542–551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayama S, Daigo Y, Yamabuki T, et al:
Phosphorylation and activation of cell division cycle associated 8
by aurora kinase B plays a significant role in human lung
carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taniwaki M, Takano A, Ishikawa N, et al:
Activation of KIF4A as a prognostic biomarker and therapeutic
target for lung cancer. Clin Cancer Res. 13:6624–6631. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mano Y, Takahashi K, Ishikawa N, et al:
Fibroblast growth factor receptor 1 oncogene partner as a novel
prognostic biomarker and therapeutic target for lung cancer. Cancer
Sci. 98:1902–1913. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato T, Sato N, Hayama S, et al:
Activation of holliday junction recognizing protein involved in the
chromosomal stability and immortality of cancer cells. Cancer Res.
67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato T, Sato N, Takano A, et al:
Activation of placenta specific transcription factor distal-less
homeobox 5 predicts clinical outcome in primary lung cancer
patients. Clin Cancer Res. 14:2363–2370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dunleavy EM, Roche D, Tagami H, et al:
HJURP is a cell-cycle-dependent maintenance and deposition factor
of CENP-A at centromeres. Cell. 137:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirata D, Yamabuki T, Miki D, et al:
Involvement of epithelial cell transforming sequence-2 oncoantigen
in lung and esophageal cancer progression. Clin Cancer Res.
15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sato N, Koinuma J, Fujita M, et al:
Activation of WD repeat and high-mobility group box DNA binding
protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer
Res. 16:226–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sato N, Koinuma J, Ito T, et al:
Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7)
protein in pulmonary carcinogenesis. Genes Chromosomes Cancer.
49:353–367. 2010.PubMed/NCBI
|
|
29
|
Nguyen MH, Koinuma J, Ueda K, et al:
Phosphorylation and activation of cell division cycle associated 5
by mitogen-activated protein kinase play a crucial role in human
lung carcinogenesis. Cancer Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishikawa N, Daigo Y, Yasui W, et al: ADAM8
as a novel serological and histochemical marker for lung cancer.
Clin Cancer Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishikawa N, Daigo Y, Takano A, et al:
Increases of amphiregulin and transforming growth factor-alpha in
serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamabuki T, Takano A, Hayama S, et al:
Dickkopf-1 as a novel serologic and prognostic biomarker for lung
and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ishikawa N, Takano A, Yasui W, et al:
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a
serologic biomarker and a therapeutic target for lung and
esophageal carcinomas. Cancer Res. 67:11601–11611. 2007. View Article : Google Scholar
|
|
34
|
Takano A, Ishikawa N, Nishino R, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sato N, Yamabuki T, Takano A, et al: Wnt
inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.
Cancer Res. 70:5326–5336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mizukami Y, Kono K, Daigo Y, et al:
Detection of novel cancer-testis antigen-specific T-cell responses
in TIL, regional lymph nodes, and PBL in patients with esophageal
squamous cell carcinoma. Cancer Sci. 99:1448–1454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Harao M, Hirata S, Irie A, et al:
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated
cancer testis antigen, cell division cycle associated 1, can induce
tumor-reactive CTL. Int J Cancer. 123:2616–2625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kono K, Mizukami Y, Daigo Y, et al:
Vaccination with multiple peptides derived from novel cancer-testis
antigens can induce specific T-cell responses and clinical
responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yokomine K, Senju S, Nakatsura T, et al:
The forkhead box M1 transcription factor, as a candidate of target
for anti-cancer immunotherapy. Int J Cancer. 126:2153–2163.
2010.PubMed/NCBI
|
|
41
|
Tomita Y, Imai K, Senju S, et al: A novel
tumor-associated antigen, cell division cycle 45-like can induce
cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci.
102:697–705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rayet B and Gelinas C: Aberrant rel/nfkb
genes and activity in human cancer. Oncogene. 18:6938–6947. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tergaonkar V: NFκB pathway: A good
signaling paradigm and therapeutic target. Int J Biochem Cell Biol.
38:1647–1653. 2006.
|
|
44
|
Yamamoto Y and Gaynor RB: Therapeutic
potential of inhibition of the NF-kappaB pathway in the treatment
of inflammation and cancer. J Clin Invest. 107:135–142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim HJ, Hawke N and Baldwin AS: NF-κB and
IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006.
|
|
46
|
O’Donnell L, Panier S, Wildenhain J, et
al: The MMS22L-TONSL complex mediates recovery from replication
stress and homologous recombination. Mol Cell. 40:619–631.
2010.PubMed/NCBI
|
|
47
|
Duro E, Lundin C, Ask K, et al:
Identification of the MMS22L-TONSL complex that promotes homologous
recombination. Mol Cell. 40:632–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brenda C, O’Connell L, Adamson B, et al: A
genome-wide camptothecin sensitivity screen identifies a mammalian
MMS22L-NFKBIL2 complex required for genomic stability. Mol Cell.
40:645–657. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Piwko W, Olma MH, Held M, et al:
RNAi-based screening identifies the Mms22L-Nfkbil2 complex as a
novel regulator of DNA replication in human cells. EMBO J.
29:4210–4222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee BJ, Chon KM, Kim YS, et al: Effects of
cisplatin, 5-fluorouracil, and radiation on cell cycle regulation
and apoptosis. Chemotherapy. 51:103–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
